MetabolicRetatrutide
20 mg · Lyophilized Powder
Higher-strength format for metabolic and receptor-signalling research.
Batch COA available by email on request
Published areas of interest.
This page summarises published research areas for general information. It does not establish safety, efficacy, or suitability for any use.
Retatrutide is an investigational peptide studied for activity at GIP, GLP-1 and glucagon receptors. Published work includes receptor studies, animal studies and controlled human clinical trials.
Areas of research interest
Current evidence
Two sponsor-funded Phase 2 randomised trials investigated retatrutide in defined adult populations. They reported group-level changes in metabolic endpoints alongside gastrointestinal adverse events and heart-rate observations. Phase 3 research is ongoing.
Important limitations
The studies used selected eligibility criteria and limited follow-up. Phase 2 findings do not establish long-term safety, outcomes in broader populations, or equivalence to material supplied outside a clinical-trial chain.
Documentation for this material.
Independently tested by ADKL Labs, Australia, August 2026. Greater than 99% purity confirmed by LC-UV. Identity confirmed by Hi-Res MS. COA available by email.
Understand our testingFor research use only.
Not for human or animal consumption. Not an approved therapeutic good. The TGA identifies Retatrutide as an unapproved therapeutic good in Australia.
How to order Retatrutide
Pay by bank transfer to Sempra Labs Pty Ltd, BSB 923100, Account 43679047, using your full name as the reference, plus $11 flat-rate shipping, then WhatsApp your remittance and order to 0428 717 379.